Top Page
Mesoblast Limited
(Sydney:MSB)
Mesoblast Limited (MSB) vs. iShares MSCI Australia ETF (EWA)
Mesoblast Limited Business Overview & Revenue Model
Mesoblast Limited Earnings Call Summary
Mesoblast Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.67M | 17.20M | 5.90M | 7.50M | 10.21M | 7.46M |
| Gross Profit | -22.57M | 12.07M | -35.17M | -47.42M | -53.36M | -78.28M |
| EBITDA | -49.42M | -73.66M | -56.08M | -58.55M | -76.57M | -84.65M |
| Net Income | -103.35M | -102.14M | -87.96M | -81.89M | -91.35M | -98.81M |
Balance Sheet | ||||||
| Total Assets | 653.32M | 784.68M | 669.15M | 669.41M | 662.14M | 744.72M |
| Cash, Cash Equivalents and Short-Term Investments | 38.03M | 161.16M | 62.56M | 70.92M | 60.03M | 136.88M |
| Total Debt | 126.11M | 128.16M | 118.92M | 116.50M | 106.91M | 105.50M |
| Total Liabilities | 192.06M | 187.24M | 188.80M | 167.58M | 165.10M | 163.32M |
| Stockholders Equity | 461.26M | 597.44M | 480.36M | 501.84M | 497.04M | 581.40M |
Cash Flow | ||||||
| Free Cash Flow | -21.07M | -50.68M | -48.79M | -63.58M | -66.01M | -108.33M |
| Operating Cash Flow | -20.66M | -49.95M | -48.46M | -63.27M | -65.78M | -106.68M |
| Investing Cash Flow | 618.00K | 120.00K | -97.00K | -194.00K | -232.00K | -1.65M |
| Financing Cash Flow | 4.39M | 147.34M | 40.25M | 74.50M | -9.87M | 114.47M |
Mesoblast Limited Technical Analysis
Mesoblast Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.41B | 16.28 | 54.79% | ― | 12.35% | 26.73% | |
73 Outperform | AU$616.97M | 17.01 | 15.90% | 0.41% | 7.76% | 1.55% | |
56 Neutral | AU$93.58M | -9.78 | -49.72% | ― | ― | 10.78% | |
55 Neutral | AU$3.55B | -21.21 | -18.95% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$552.65M | -8.89 | -35.86% | ― | ― | -19.21% | |
41 Neutral | AU$276.51M | -28.41 | -89.70% | ― | 42.05% | -0.84% |
Mesoblast Limited Corporate Events
Mesoblast Limited announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York, where CEO Silviu Itescu will engage in a fireside chat. This participation underscores Mesoblast’s active engagement with the healthcare investment community and highlights its strategic focus on expanding the reach of its innovative cellular therapies. The company’s presence at such events is crucial for maintaining its industry positioning and fostering relationships with stakeholders, potentially impacting its market influence and growth trajectory.
Mesoblast Limited, in collaboration with the NIH-funded Blood and Marrow Transplant Clinical Trials Network, is initiating a pivotal trial for Ryoncil® as a first-line treatment for adults with severe acute graft versus host disease (aGvHD) who are refractory to steroids. This trial aims to address the high non-responsiveness and mortality rates in these patients, offering a potentially life-saving treatment that has shown promising survival rates in previous studies. The trial represents a significant market opportunity, expanding the use of Ryoncil® beyond the pediatric population and addressing a major unmet medical need.
Mesoblast Limited has appointed James M. O’Brien as its new Chief Financial Officer, a strategic move as the company transitions to a fully integrated commercial organization. O’Brien’s extensive experience in financial management within the life sciences and pharmaceutical industries is expected to bolster Mesoblast’s financial leadership, aiding in the commercialization of its products and potential expansion into new markets.
Mesoblast Limited announced a scheduled meeting with the FDA to discuss data from its Phase 3 study of rexlemestrocel-L for opioid reduction in chronic low back pain patients. The study showed significant opioid cessation results, highlighting the potential impact of rexlemestrocel-L as a non-opioid treatment option amid the ongoing opioid crisis in the US. The FDA has recognized the importance of developing non-opioid treatments, and Mesoblast is actively recruiting for a confirmatory Phase 3 trial. The outcome of these discussions could significantly influence Mesoblast’s positioning in the market and offer a promising solution for patients with chronic low back pain.
Mesoblast Limited announced a change in the director’s interest, with William Burns exercising options to acquire 120,000 ordinary shares, increasing his total holdings to 226,250 shares. This transaction, valued at A$157,200, reflects strategic financial management and potentially strengthens the director’s commitment to the company’s future growth.
Mesoblast Limited has released its Annual Report for 2025, highlighting its commitment to corporate governance and ethical management. The report, approved by the Board of Directors, outlines the company’s governance framework, emphasizing its dedication to transparency and accountability, which is crucial for maintaining stakeholder trust and industry leadership.
Mesoblast Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, in Melbourne. The company encourages shareholders to attend in person or view the meeting online. Shareholders can vote in person or by proxy and are invited to submit questions in advance. This AGM is a crucial event for stakeholders to engage with the company’s management and discuss its performance and strategic direction.
Mesoblast Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This release is significant as it reinforces Mesoblast’s dedication to maintaining high governance standards, potentially impacting investor confidence and stakeholder trust.
Mesoblast Limited reported a significant 69% increase in net revenues for its product Ryoncil® in the second quarter following its launch, driven by increased physician adoption and reimbursement from commercial and government payers. The assignment of a permanent J-Code by the Centers for Medicare and Medicaid Services is expected to further enhance product adoption. The company has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. Mesoblast is also planning a pivotal trial for Ryoncil® in adults with severe SR-aGvHD, potentially expanding its market reach. The company holds a strong cash position and is exploring additional funding options to support its operations and growth.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the development of regenerative medicine products. The change in their substantial holding status is due to various transactions involving securities lending, purchasing, and sales, as well as the rehypothecation of client securities. This shift in holdings may impact Mesoblast’s market perception and investor confidence, as JPMorgan’s involvement was significant in terms of voting securities.
Mesoblast Limited announced the cessation of certain securities, with 120,000 options lapsing due to unmet conditions and over 2 million options expiring without exercise. This development may impact the company’s financial strategy and investor relations, as it reflects on the company’s ability to meet certain operational milestones.
Mesoblast Limited announced the application for the quotation of 3,000,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities are issued under an employee incentive scheme and are not subject to transfer restrictions. This move is part of Mesoblast’s strategy to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement positively.
Mesoblast Limited reported a significant 66% increase in revenue for its product Ryoncil, reaching US$21.9 million in the second quarter post-launch. This growth is attributed to the adoption of Ryoncil for treating pediatric steroid-refractory acute graft-versus-host disease, supported by reimbursement from commercial and government payers. The recent assignment of a permanent J-Code by the Centers for Medicare and Medicaid Services is expected to further enhance product adoption. This development strengthens Mesoblast’s position in the cellular medicine industry and indicates positive implications for stakeholders, highlighting the company’s potential for continued growth and market expansion.
Mesoblast Limited announced that its product Ryoncil® has received a permanent J-Code from the United States Medicare & Medicaid Services, facilitating easier billing and reimbursement. This milestone is expected to enhance patient access to Ryoncil®, particularly for children with life-threatening steroid-refractory acute graft-versus-host disease, and improve the product’s commercialization prospects.
Mesoblast Limited announced that its allogeneic cell therapy products, manufactured in the U.S. from U.S. donors, are designated as U.S. origin products and are not subject to tariffs on imported branded or patented pharmaceutical products. This designation, particularly for Ryoncil®, the only FDA-approved allogeneic mesenchymal stromal cell therapy, reinforces Mesoblast’s strategic positioning in the market by ensuring cost stability and regulatory compliance, potentially benefiting stakeholders by maintaining competitive pricing and access in the U.S. market.
Mesoblast Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders in the company as of September 18, 2025. This change in substantial holding could impact Mesoblast’s shareholder composition and influence voting dynamics, potentially affecting the company’s strategic decisions and market positioning.
Mesoblast Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders of the company’s voting securities as of September 11, 2025. This change in substantial holding may impact Mesoblast’s shareholder structure and could influence the company’s strategic decisions and market perception.
Mesoblast Limited announced the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell product, at global healthcare conferences. The company reported strong initial sales for treating pediatric SR-aGvHD and plans to expand Ryoncil® into adult SR-aGvHD and inflammatory bowel disease, alongside advancing its second-generation product Rexlemestrocel-L. This launch and expansion strategy is expected to enhance Mesoblast’s market positioning and operational growth in the cellular medicine industry.
Mesoblast Limited has announced a change in the director’s interest, specifically pertaining to Gregory George. The company disclosed that George, through G to the Fourth Investments, LLC, acquired 9,640,072 shares and 325,901 American Depositary Shares (ADS), each representing 10 ordinary shares, in an on-market purchase. This acquisition reflects a significant investment amounting to approximately US$18.8 million, indicating a potential strategic move to strengthen his stake in the company.